Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STC 15

Next Previous
Drug Profile

STC 15

Alternative Names: STC-15

Latest Information Update: 10 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evotec SE; Storm Therapeutics
  • Class Amides; Amines; Antineoplastics; Cyclobutanes; Indoles; Ketones; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action METTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer
  • Phase I Solid tumours
  • No development reported Acute myeloid leukaemia; Haematological malignancies

Most Recent Events

  • 27 May 2025 STORM Therapeutics enters a collaboration and supply agreement with Coherus Bioscience for a phase I/II trial for STC 15
  • 27 May 2025 Updated efficacy data from a phase I trial in Solid tumours released by STORM Therapeutics
  • 05 May 2025 Phase-I/II clinical trials in Endometrial cancer (Combination therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT06975293)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top